AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells

Abstract

Acute myeloid leukemia (AML) cells carry molecular defects that promote their leukemic proliferation, resistance to apoptosis and defect in differentiation. Pharmacological targeting of the nuclear factor kappaB (NF-κB) pathway has been shown to promote apoptosis of primary AML cells and to sensitize blasts to neoplastic drugs (Frelin, Blood 2005, 105, 804… (More)
DOI: 10.1038/sj.leu.2404614

Topics

6 Figures and Tables

Cite this paper

@article{Grieinger2007AS602868AD, title={AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells}, author={Eric Grie\ssinger and V{\'e}ronique Imbert and Patricia Lagadec and Nad{\`e}ge Gonthier and Pascale Dubreuil and Angela Romanelli and Michel Dreano and J. F. Peyron}, journal={Leukemia}, year={2007}, volume={21}, pages={877-885} }